(3S)-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2S)-2-[(2S)-3-(1H-indol-3-yl)-2-(3-{[(2-methylpropoxy)carbonyl]amino}propanamido)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid

• ChemBase编号: 68
• 分子式: C37H49N7O9S
• 平均质量: 767.89146
• 单一同位素质量: 767.33124718
• SMILES: S(CC[C@H](NC(=O)[C@@H](NC(=O)CCNC(=O)OCC(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N)C
• Canonical SMILES: CSCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)CCNC(=O)OCC(C)C
• InChI: InChI=1S/C37H49N7O9S/c1-22(2)21-53-37(52)39-15-13-31(45)41-29(18-24-20-40-26-12-8-7-11-25(24)26)35(50)42-27(14-16-54-3)34(49)44-30(19-32(46)47)36(51)43-28(33(38)48)17-23-9-5-4-6-10-23/h4-12,20,22,27-30,40H,13-19,21H2,1-3H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t27-,28-,29-,30-/m0/s1
• InChIKey: ALXRNCVIQSDJAO-KRCBVYEFSA-N

名称和登记号

名称

• IUPAC标准名: (3S)-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2S)-2-[(2S)-3-(1H-indol-3-yl)-2-(3-{[(2-methylpropoxy)carbonyl]amino}propanamido)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid
• IUPAC传统名: peptavlon
• 商标名: Peptavlon
• 别名: Pentagastrin

登记号

• CAS号: 5534-95-2
• PubChem SID: 46507747; 160963531
• PubChem CID: 444007

理论计算性质

JChem

• Acid pKa: 3.996262
• 质子受体: 8
• 质子供体: 8
• LogD (pH = 5.5): -0.2730803
• LogD (pH = 7.4): -1.9212354
• Log P: 1.2399907
• 摩尔折射率: 199.9748 cm^3
• 极化性: 79.07773 Å^3
• 极化表面积: 250.91 Å^2
• 可自由旋转的化学键: 23
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 1.57
• LOG S: -5.4
• 溶解度: 3.09e-03 g/l

分子性质

理化性质

• 疏水性(logP): 1.6

详细说明

DrugBank - DB00183

• Drug Groups: approved
• Description: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. [PubChem]
• Indication: Used as a diagnostic aid for evaluation of gastric acid secretory function
• Pharmacology: Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection.
• Affected Organisms: Humans and other mammals
• Biotransformation: Primarily hepatic
• Absorption: Rapidly absorbed after parenteral administration.
• Half Life: 10 minutes or less
• References: Weintraub HS, Rudolph A: Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations. Am J Ther. 2010 Jun 9. [Pubmed]
• External Links: Wikipedia

参考文献

• Weintraub HS, Rudolph A: Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations. Am J Ther. 2010 Jun 9. Pubmed